Johnson & Johnson Reports TREMFYA PsA Study Findings
The company said TREMFYA demonstrated MRI-confirmed improvements in spinal pain and stiffness. The available report also says the treatment showed statistically significant improvement on the BASDAI disease activity score versus an unspecified comparator.